Voices of Alzheimer’s responds to misleading attacks on amyloid research, highlighting real breakthroughs—FDA-approved treatments, earlier diagnosis, and renewed hope for patients.

Voices of Alzheimer’s releases statement in response to federal healthcare cuts that endanger patients.

Voices of Alzheimer’s Writes Sign-On Letter to Address CMS’s Proposed Reimbursement for Alzheimer’s Blood Tests

Voices of Alzheimer's Signs on to Letter to CMS with Sister Organizations

Voices of Alzheimer's Applauds the FDA's Approval of Donanemab for Early Alzheimer's

Voices of Alzheimer's Applauds FDA Advisory Panel's Endorsement of Donanemab.

Voices of Alzheimer’s leads letter urging CMS to address payment bundling policies that effect individuals living with and at risk of Alzheimer’s.

Amid the Discontinuation of Biogen’s Aduhelm, We Urge Biogen to Prioritize Patient Support.

Two Steps Forward, One Step Back: Voices of Alzheimer's Applauds Medicare's Progress in Removing CED for Amyloid PET Scans but Calls Out its Failure to Ensure Expeditious and Equitable Coverage.

VoA's Official Public Comment On CMS's Broader PET Scan Coverage Proposal.

VoA Celebrates Groundbreaking Donanemab Clinical Trial Results.

VoA Celebrates the FDA’s Historic Traditional Approval of Leqembi for Early Alzheimer’s and Positive Movement on Medicare Access.

Medicare is treating people with Alzheimer's differently - here's how.

Read our recent whitepaper on the Historic and Ongoing Discrimination of Medicare Against People Living with Alzheimer's.

Statement on CMS’ ‘Plan to Ensure Availability of New Alzheimer’s Drugs’.

Vast Majority of American Voters Demand Action Against Medicare’s Incompetence.

A Statement from the CEO of Voices of Alzheimer's in Response to Recent Comments Regarding Medicare Coverage for New Treatments.

Voices of Alzheimer's Demands CMS End Discrimination Against Alzheimer's Patients and Expand Access to New Treatments in Light of Groundbreaking Donanemab Research Results.

A Statement from the CEO of Voices of Alzheimer's in Response to Recent Comments Regarding Medicare Coverage for New Treatments.

Voices of Alzheimer’s signed onto a letter along with 32 other organizations addressing the unmet clinical need for agitation associated with Alzheimer’s disease. Read the compelling piece here.

President and CEO of VoA, Jim Taylor, spoke during the FDA Open Public Hearing on Rexulti for the treatment of agitation associated with Alzheimer’s dementia. Read what he had to say here.

Voices of Alzheimer’s has responded to the Dept. of Veterans Affairs announcement that it will cover new treatments for people with Alzheimer’s.

VoA responds to the latest announcement from CMS regarding coverage for treatments for Alzheimer’s disease.

VoA CEO Jim Taylor made comments to the Medicare Evidence Development & Coverage Advisory group regarding CMS coverage under CED.

VoA’s CEO Jim Taylor commented at the NAPA Advisory Council meeting.

Read VoA’s response to ICER’s Draft Evidence Report assessing the comparative clinical effectiveness and value of emerging treatments.

See our reaction to the FDA announcing the expedited approval of Lecanemab.

See our press release on the latest clinical trial results and what they mean for patients.

See the letter we signed to President Biden on PET scans for Alzheimer’s.

See our press release on the latest research announcement from Roche on gantenerumab.

See our press release announcing the launch of Voices of Alzheimer’s.

See our press release calling on CMS to reverse course on coverage for new treatments.

Nov See a policy letter from 20 organizations to the Dept. of Health and Human Services on coverage requirements.

VoA signed this policy letter with other nonprofit organizations in support of PET scans for Alzheimer’ssigned this policy letter with other nonprofit organizations in support of PET scans for Alzheimer’s.

While scientific integrity must be taken seriously, sweeping claims that amyloid research has wasted time or set us back ignore the significant progress made and the lives already improved.

Jim Taylor shares his insights on the need for a patient advocacy perspective in the FDA drug review process.

Geri Taylor benefitted from now-discontinued Alzheimer's drug for seven years.

VoA Champion Dan Jaworski expresses his concerns over the lack of treatment options available for individuals living with the disease.

VoA Champion Mike Zuendel addresses frustration with CMS in light of newly approved Alzheimer’s treatments.

VoA Board Member Jay Reinstein was interviewed by the Washington Post about accessing Leqembi, a new drug that slows Alzheimer’s disease.

VoA Champion, Dr. Alan Schooley

VoA Champion Michele Hall

VoA Member Bob Toia

VoA Board Member Jay Reinstein protests for Medicare coverage of Alzheimer’s drugs.

VoA Board Members Sue Peschin and Jay Reinstein were interviewed by Bloomberg, weighing in on the Medicare coverage of Leqembi.

VoA Board Member Philip Gutis wrote an op-ed for the Post-Gazette about recent breakthroughs in Alzheimer’s.